Galecto Announces Pricing of $275 Million Underwritten Public Offering

Core Viewpoint - Galecto, Inc. has announced a public offering of 14,473,685 shares of common stock at a price of $19.00 per share, aiming to raise approximately $275 million in gross proceeds before expenses [1][2]. Group 1: Offering Details - The offering includes a 30-day option for underwriters to purchase an additional 2,171,052 shares at the same public offering price [1]. - The expected closing date for the offering is around February 12, 2026, subject to customary closing conditions [2]. Group 2: Company Overview - Galecto, Inc. is a clinical-stage biotechnology company focused on developing antibody therapeutics for hematological cancers [5]. - The company's pipeline includes a mutant calreticulin (mut-CALR)-driven myeloproliferative neoplasm portfolio and GB3226, a first-in-class preclinical dual inhibitor for acute myeloid leukemia [5].